Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis

M. Okano

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Summary Allergic rhinitis is a common airway disease characterized by hypersensitivity, exudation, hypersecretion, inflammatory cell infiltration and remodelling. Intranasal glucocorticosteroids are the most effective drugs for controlling the inflammation caused by allergic rhinitis. Glucocorticosteroids exert anti-inflammatory effects through at least two pathways: the transactivation pathway and the transrepression pathway. Glucocorticosteroids also exert regulatory functions by inducing regulatory cytokines and forkhead box P3 (FoxP3+) regulatory T cells. Evidence suggests that intranasal glucocorticosteroids control not only nasal symptoms but also ocular symptoms. In contrast to sedating H1 receptor antagonists, intranasal glucocorticosteroids can improve impaired performance symptoms, such as daytime sleepiness, associated with allergic rhinitis. Recent studies suggest that intranasal glucocorticosteroids might also be useful for the prophylactic treatment of pollinosis; this possibility is supported by the molecular mechanism of the anti-inflammatory action of glucocorticosteroids. These findings suggest that intranasal glucocorticosteroids might be positioned as first-line drugs for the treatment of both perennial and seasonal allergic rhinitis.

Original languageEnglish
Pages (from-to)164-173
Number of pages10
JournalClinical and Experimental Immunology
Volume158
Issue number2
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Seasonal Allergic Rhinitis
Anti-Inflammatory Agents
Histamine H1 Receptors
Regulatory T-Lymphocytes
Nose
Pharmaceutical Preparations
Transcriptional Activation
Hypersensitivity
Cytokines
Inflammation
Allergic Rhinitis

Keywords

  • Impaired performance
  • Intranasal glucocorticosteroids
  • Ocular symptoms
  • Regulatory T cells

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis. / Okano, M.

In: Clinical and Experimental Immunology, Vol. 158, No. 2, 11.2009, p. 164-173.

Research output: Contribution to journalArticle

@article{5f6a95206d6a4d89965de81d524a55d3,
title = "Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis",
abstract = "Summary Allergic rhinitis is a common airway disease characterized by hypersensitivity, exudation, hypersecretion, inflammatory cell infiltration and remodelling. Intranasal glucocorticosteroids are the most effective drugs for controlling the inflammation caused by allergic rhinitis. Glucocorticosteroids exert anti-inflammatory effects through at least two pathways: the transactivation pathway and the transrepression pathway. Glucocorticosteroids also exert regulatory functions by inducing regulatory cytokines and forkhead box P3 (FoxP3+) regulatory T cells. Evidence suggests that intranasal glucocorticosteroids control not only nasal symptoms but also ocular symptoms. In contrast to sedating H1 receptor antagonists, intranasal glucocorticosteroids can improve impaired performance symptoms, such as daytime sleepiness, associated with allergic rhinitis. Recent studies suggest that intranasal glucocorticosteroids might also be useful for the prophylactic treatment of pollinosis; this possibility is supported by the molecular mechanism of the anti-inflammatory action of glucocorticosteroids. These findings suggest that intranasal glucocorticosteroids might be positioned as first-line drugs for the treatment of both perennial and seasonal allergic rhinitis.",
keywords = "Impaired performance, Intranasal glucocorticosteroids, Ocular symptoms, Regulatory T cells",
author = "M. Okano",
year = "2009",
month = "11",
doi = "10.1111/j.1365-2249.2009.04010.x",
language = "English",
volume = "158",
pages = "164--173",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis

AU - Okano, M.

PY - 2009/11

Y1 - 2009/11

N2 - Summary Allergic rhinitis is a common airway disease characterized by hypersensitivity, exudation, hypersecretion, inflammatory cell infiltration and remodelling. Intranasal glucocorticosteroids are the most effective drugs for controlling the inflammation caused by allergic rhinitis. Glucocorticosteroids exert anti-inflammatory effects through at least two pathways: the transactivation pathway and the transrepression pathway. Glucocorticosteroids also exert regulatory functions by inducing regulatory cytokines and forkhead box P3 (FoxP3+) regulatory T cells. Evidence suggests that intranasal glucocorticosteroids control not only nasal symptoms but also ocular symptoms. In contrast to sedating H1 receptor antagonists, intranasal glucocorticosteroids can improve impaired performance symptoms, such as daytime sleepiness, associated with allergic rhinitis. Recent studies suggest that intranasal glucocorticosteroids might also be useful for the prophylactic treatment of pollinosis; this possibility is supported by the molecular mechanism of the anti-inflammatory action of glucocorticosteroids. These findings suggest that intranasal glucocorticosteroids might be positioned as first-line drugs for the treatment of both perennial and seasonal allergic rhinitis.

AB - Summary Allergic rhinitis is a common airway disease characterized by hypersensitivity, exudation, hypersecretion, inflammatory cell infiltration and remodelling. Intranasal glucocorticosteroids are the most effective drugs for controlling the inflammation caused by allergic rhinitis. Glucocorticosteroids exert anti-inflammatory effects through at least two pathways: the transactivation pathway and the transrepression pathway. Glucocorticosteroids also exert regulatory functions by inducing regulatory cytokines and forkhead box P3 (FoxP3+) regulatory T cells. Evidence suggests that intranasal glucocorticosteroids control not only nasal symptoms but also ocular symptoms. In contrast to sedating H1 receptor antagonists, intranasal glucocorticosteroids can improve impaired performance symptoms, such as daytime sleepiness, associated with allergic rhinitis. Recent studies suggest that intranasal glucocorticosteroids might also be useful for the prophylactic treatment of pollinosis; this possibility is supported by the molecular mechanism of the anti-inflammatory action of glucocorticosteroids. These findings suggest that intranasal glucocorticosteroids might be positioned as first-line drugs for the treatment of both perennial and seasonal allergic rhinitis.

KW - Impaired performance

KW - Intranasal glucocorticosteroids

KW - Ocular symptoms

KW - Regulatory T cells

UR - http://www.scopus.com/inward/record.url?scp=70349671187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349671187&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2249.2009.04010.x

DO - 10.1111/j.1365-2249.2009.04010.x

M3 - Article

C2 - 19737138

AN - SCOPUS:70349671187

VL - 158

SP - 164

EP - 173

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 2

ER -